Stay updated on Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2FSe4c4lrIYfiOCg6vk_Vwfx-OBWk.uncropped.jpg&w=3840&q=75)
Latest updates to the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- CheckyesterdayNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, replacing the previous version v2.9.7.SummaryDifference0.4%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus Genetics related topics: Melanoma MedlinePlus related topics: Melanoma Genetic and Rare Diseases Information Center resources: Neuroendocrine Tumor Neuroepithelioma Drug Information available for: Ipilimumab Nivolumab Relatlimab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : Non-Randomized Interventional Model : Parallel Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Arm A Nivolumab and Relatlimab Drug : Nivolumab Nivolumab will be given by vein on day 1 of each cycle. Drug : Relatlimab Relatlimab will be given by vein on day 1 of each 28-day cycle Experimental : Arm B Nivolumab and Ipilimumab Drug : Nivolumab Nivolumab will be given by vein on day 1 of each cycle. Drug : Ipilimumab Ipilimumab will be given by vein on day 1 during cycles 1-4 (cycles are 21 days). Primary Outcome Measures Outcome Measure Measure Description Time Frame Change in Activated GZMB+ CD8+T-cell Density Intratumorally, of Two Immunotherapy Regimens Approximately 16 months Secondary Outcome Measures Outcome Measure Measure Description Time Frame Response Rate Approximately 16 months Median Progression Free Survival Approximately 16 months Median Overall Survival Approximately 16 months Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE Version 5.0 Up to 30 days from last dose of drugs (average of 13 cycles) Additional Relevant MeSH Terms Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Neoplasms by Site Skin Diseases Melanoma Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Nivolumab Ipilimumab Relatlimab Plan to Share Individual Participant Data (IPD)? Undecided Studies a U.S. FDA-Regulated Drug Product Yes Studies a U.S. FDA-Regulated Device Product No Study Documents Provided by Elizabeth Davis, Vanderbilt-Ingram Cancer Center Study Protocol and Statistical Analysis Plan [ PDF , 4.72MB, 2020-03-30 ] Revision: v2.9.1'SummaryDifference14%
Stay in the know with updates to Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.